Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib

Open access
Motzer, Robert J., Hutson, Thomas E., McCann, Lauren, Deen, Keith, Choueiri, Toni K.·2014·New England Journal of Medicine

Abstract

Ellison notes that ethical clinical trials should be testing hypotheses based on equipoise; thus, we should expect approximately 50% of trials to support the null hypothesis, whereby a new treatment will not prove to be better than a standard one.We agree completely with this philosophical premise and recognize that a well-designed and well-conducted "null study" is a successful trial.The treatment of diabetic kidney disease would have greatly advanced over the past several decades if 50% of relevant clinical trials had shown efficacy, which unfortunately has not been the case.Within the framework of equipoise, every effort should be made to maximize patient safety, which should always be the paramount concern in study design.The BEACON trial was terminated early because of strong adverse safety signals in study participants who received bardoxolone methyl as compared with those who received placebo.The study did not continue long enough to fully determine the efficacy of the drug for slowing the progression of diabetic kidney disease.We continue to emphasize the need for greater rigor in preclinical testing, careful evaluations of dosing, improved methods for off-target toxicity testing, and biomarker development.We also stress the need for business and regulatory environments that foster innovation.Other authors have also recently called for similar approaches to improving the drug-development process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1400731

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 271

Metadata

Authors
Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K.
Venue
New England Journal of Medicine
Published
2014-05
Volume
370
Issue
18
Pages
1769-1770
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2316731546
Cited by
271
References
2
FWCI
26.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. https://app.cochat.ai/papers/10.1056/nejmc1400731
The paper
Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K. (2014). Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. New England Journal of Medicine. https://doi.org/10.1056/nejmc1400731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.